A Phase 1b Open-Label Dose-Escalating Study to Evaluate the Safety and Tolerability of PLG0206 in Patients Undergoing Debridement Antibiotics and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)

Brief description of study

The purpose of this study is to learn about the effects of a study drug, PLG0206, to find the best dose for treating periprosthetic joint infections (PJI) (an infection around your artificial knee) in conjunction with the DAIR (debridement (cleaning the wound and removing any dead tissue), antibiotics and implant retention) surgical procedure followed by an approximate 6-week course of antimicrobial therapy that is standard-of-care (SOC) for treatment of this condition, and to see how safe PLG0206 is for patients with periprosthetic joint infections (PJI) after total knee arthroplasty (TKA).

Clinical Study Identifier: s22-00513
ClinicalTrials.gov Identifier: NCT05137314

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.